Humog 75 Injection contains Menotrophin (75 IU), a purified gonadotropin preparation derived from the urine of postmenopausal women. It is indicated for use in the treatment of infertility in both males and females by stimulating follicular development in women and spermatogenesis in men. In females, Humog 75 is primarily employed in cases of anovulation due to hypogonadotropic hypogonadism, polycystic ovary syndrome, or other ovulatory disorders where endogenous gonadotropin secretion is inadequate. The administration of Menotrophin promotes the maturation of ovarian follicles, facilitating ovulation and increasing the chances of conception. In males, it is used to induce spermatogenesis in patients with hypogonadotropic hypogonadism, thereby improving sperm count and motility. The dosage and duration of treatment should be individualized based on patient response and monitored through clinical and laboratory parameters, including serum estradiol levels and ultrasound assessment of follicular growth. Humog 75 Injection is administered via intramuscular or subcutaneous injection under medical supervision. Common adverse effects may include ovarian hyperstimulation syndrome, injection site reactions, and multiple pregnancies. Careful monitoring is essential to minimize risks and optimize therapeutic outcomes. This product should be used only under the guidance of a qualified healthcare professional experienced in fertility treatments.